These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11291833)

  • 1. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
    Miya T; Goya T; Fujii H; Ohtsu T; Itoh K; Igarashi T; Minami H; Sasaki Y
    Invest New Drugs; 2001; 19(1):61-7. PubMed ID: 11291833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
    Sasaki Y; Hakusui H; Mizuno S; Morita M; Miya T; Eguchi K; Shinkai T; Tamura T; Ohe Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):101-10. PubMed ID: 7737901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
    Kimura T; Kashiwase S; Makimoto A; Kumagai M; Taga T; Ishida Y; Ida K; Nagatoshi Y; Mugishima H; Kaneko M; Barrett JS
    Int J Clin Pharmacol Ther; 2010 May; 48(5):327-34. PubMed ID: 20420789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
    Wu H; Infante JR; Keedy VL; Jones SF; Chan E; Bendell JC; Lee W; Kirschbrown WP; Zamboni BA; Ikeda S; Kodaira H; Rothenberg ML; Burris HA; Zamboni WC
    Int J Nanomedicine; 2015; 10():1201-9. PubMed ID: 25709442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
    Mick R; Gupta E; Vokes EE; Ratain MJ
    J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG
    Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
    Mathijssen RH; Verweij J; de Jonge MJ; Nooter K; Stoter G; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(1):81-7. PubMed ID: 11773157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
    Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
    Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
    Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
    Sasaki Y; Mizuno S; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K; Sekine I; Miyata Y; Saijo N
    Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J; Aldaz A; Castellanos C; Calvo E; Giráldez J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):159-68. PubMed ID: 10821401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
    Sloan JA; Atherton P; Reid J; Pitot HC; Erlichman C; Schaaf L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):241-9. PubMed ID: 11592347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.